On December 12, 2025, Morgan Stanley reaffirmed its Underweight rating for Bristol-Myers Squibb Company – Preferred Security (OTCPK:BMYMP). As of December 6, the average one-year price target for the security is $907.12 per share, suggesting a potential upside of 22.58% from its latest closing price of $740.00.
The projected annual revenue for Bristol-Myers Squibb is $49.03 billion, reflecting a 2.07% increase. Institutional ownership has seen a slight rise, with 14 funds reporting positions, a 7.69% increase from the previous quarter; however, total shares owned have remained stable at 1.38 million shares.
